Further molecular classification for wildtype GBM includes identification of one or more of the following: mutations found in the TERT promoter, amplification of epidermal growth factor receptor (EGFR) and chromosome 7 gain (partial or complete)/chromosome 10 loss [262,263,264,265]. This evidence concerns the gene EGFR and glioblastoma.